{
  "docId": "019de076-4f8b-70c9-adf8-0b3abb8c1303",
  "docSlug": "1af2d4156bf2490b3ac2801b5487abdf",
  "documentTitle": "Larimar Therapeutics | Investor Presentation Deck | 44 slides",
  "authorId": "larimar-therapeutics",
  "authorName": "Larimar Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 44,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide highlights high completion rates and manageable adverse events, specifically noting injection site reactions (ISRs) as the most common side effect.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4f8b-70c9-adf8-0b3abb8c1303/14",
  "deckHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303",
  "deckJsonHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303.json",
  "deckAnchorHref": "/decks/019de076-4f8b-70c9-adf8-0b3abb8c1303#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.215
      },
      "kind": "list",
      "text": "35 of 37 clinical trial participants dosed with nomlabofusp completed their respective study. One Phase 2 participant withdrew due to an allergic reaction. One Phase 1 participant in the 50 mg cohort withdrew due to nausea and vomiting.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bdb57b5e-f807-4392-80b8-a6079fdab405",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.735
      },
      "kind": "list",
      "text": "In MAD study, except for ISRs, number & severity of AEs did not increase with increasing dose",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8116c3f-cf30-4a57-8154-23fa5b40805f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.56
      },
      "kind": "list",
      "text": "Most common adverse events (AEs) were mild and moderate injection site reactions (ISRs). No study discontinuations due to ISRs and all resolved. ISRs in 100% of nomlabofusp-treated participants and 40% of placebo-treated participants.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb4cc9ad-742b-4555-9e05-7ed9c7c1608b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.385
      },
      "kind": "list",
      "text": "No serious adverse events or important medical events in any nomlabofusp clinical trial. One severe adverse event (allergic reaction that resolved with standard treatment referenced above).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5e103d3-dd54-4e17-b4d0-d88d1a48ce88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.94,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Nomlabofusp (CTI-1601) administered to 37 different adults with FA in multiple studies",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e04793d-bbc4-414a-bf9e-f317ab28e5ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.75,
        "x": 0.14,
        "y": 0.915
      },
      "kind": "source-note",
      "text": "*Based on Phase 1 study data and Phase 2 study 25 mg cohort data. Data excludes Phase 2 study 50 mg cohort data; data remains blinded as participants are completing the follow up period.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4229024-7c2e-4fff-aa7e-ffcb3e27af3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Ph1 & Ph2 Data: Nomlabofusp is Generally Well Tolerated*",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1612816d-38ab-4150-9fc9-aca704e3dde8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 44,
      "from": 4,
      "beatId": "800ed350-717e-4cf5-a054-3d6626879633",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Multiple pages showcase clinical trial progress and data",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}